China SXT Pharmaceuticals (SXTC) announced as part of its Artificial Intelligence Insight Initiative to explore the application of Artificial Intelligence and related digital technologies across the Traditional Chinese Medicine, TCM, raw-material supply chain. This initiative is part of the Company’s long-term plan to improve supply chain transparency, operational stability, and quality oversight. “Applying AI to our supply chain management is an important part of our long-term operational planning,” said Feng Zhou, Co-Chief Executive Officer and Director of China SXT. “Through the use of digital tools and AI-supported analysis, we aim to enhance supply chain reliability and strengthen our quality assurance capabilities.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTC:
- China SXT Pharmaceuticals Raises $9.1 Million in Registered Direct Offering with Pre-Funded Warrants
- China SXT Pharmaceuticals announces $10M registered direct offering
- Why Is Penny Stock China SXT (SXTC) Up Almost 200% Today?
- Midday Fly By: Defense stocks surge on Trump budget request
- China SXT announces launch of Strategic AI Insights Initiative